Total Payments
$103,336
2024 Payments
$21.23
Companies
59
Transactions
671
Medicare Patients
438
Medicare Billing
$82,408
Payment Breakdown by Category
Research$79,632 (77.1%)
Food & Beverage$14,487 (14.0%)
Consulting$7,730 (7.5%)
Travel$989.05 (1.0%)
Education$347.71 (0.3%)
Other$150.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $79,632 | 13 | 77.1% |
| Food and Beverage | $14,487 | 631 | 14.0% |
| Consulting Fee | $7,730 | 6 | 7.5% |
| Travel and Lodging | $989.05 | 4 | 1.0% |
| Education | $347.71 | 16 | 0.3% |
| Honoraria | $150.00 | 1 | 0.1% |
Payments by Type
Research
$79,632
13 transactions
General
$23,704
658 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $71,149 | 90 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,005 | 11 | $0 (2021) |
| Clovis Oncology, Inc. | $3,428 | 5 | $0 (2019) |
| Heron Therapeutics, Inc. | $2,780 | 5 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,614 | 13 | $0 (2019) |
| Celgene Corporation | $1,965 | 19 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,512 | 50 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $1,413 | 60 | $0 (2020) |
| Alexion Pharmaceuticals, Inc. | $1,382 | 13 | $0 (2021) |
| Incyte Corporation | $1,154 | 22 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.23 | 1 | ABBVIE INC. ($21.23) |
| 2023 | $17.81 | 1 | Pharmacyclics LLC, An AbbVie Company ($17.81) |
| 2021 | $10,100 | 8 | Takeda Pharmaceuticals U.S.A., Inc. ($6,267) |
| 2020 | $10,606 | 96 | E.R. Squibb & Sons, L.L.C. ($6,551) |
| 2019 | $67,493 | 194 | E.R. Squibb & Sons, L.L.C. ($60,079) |
| 2018 | $5,856 | 183 | Boehringer Ingelheim Pharmaceuticals, Inc. ($896.01) |
| 2017 | $9,242 | 188 | Heron Therapeutics, Inc. ($2,780) |
All Payment Transactions
671 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/14/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,143.75 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | ||||||
| 08/02/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $902.02 | Research |
| Study: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION | ||||||
| 08/02/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $163.75 | Research |
| Study: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION | ||||||
| 08/02/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $27.50 | Research |
| Study: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION | ||||||
| 05/07/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $2,886.34 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | ||||||
| 05/07/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,143.75 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | ||||||
| 02/23/2021 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Honoraria | Cash or cash equivalent | $150.00 | General |
| Category: Immunology | ||||||
| 02/04/2021 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | — | Cash or cash equivalent | $3,682.80 | Research |
| Study: Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab • Category: Oncology | ||||||
| 12/30/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $13.26 | General |
| Category: Oncology | ||||||
| 12/28/2020 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $28.35 | General |
| Category: Optune | ||||||
| 12/23/2020 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 12/16/2020 | EMD Serono, Inc. | Bavencio (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: Oncology | ||||||
| 12/16/2020 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $21.10 | General |
| 12/16/2020 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: Oncology | ||||||
| 12/14/2020 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2020 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Oncology | ||||||
| 12/07/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2020 | Immunomedics, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 11/25/2020 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/23/2020 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $19.46 | General |
| 11/19/2020 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $24.94 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab | E.R. Squibb & Sons, L.L.C. | $69,945 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $5,174 | 3 |
| Afatinib in elderly EGFR M & NSCLC | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,470 | 2 |
| A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ORAL IXAZOMIB MAINTENANCE THERAPY AFTER INITIAL THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA NOT TREATED WITH STEM CELL TRANSPLANTATION | Takeda Pharmaceuticals U.S.A., Inc. | $1,093 | 3 |
| PNH Registry | Alexion Pharmaceuticals, Inc. | $900.00 | 1 |
| BAY 1841788 AR Antagonist Prostate CA Phase lll ARAMIS | Bayer HealthCare Pharmaceuticals Inc. | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 11 | 438 | 1,812 | $160,379 | $82,408 |
Total Patients
438
Total Services
1,812
Medicare Billing
$82,408
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 99 | 430 | $63,960 | $39,369 | 61.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 12 | 131 | $41,920 | $17,192 | 41.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 44 | 86 | $8,540 | $5,280 | 61.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 13 | 79 | $13,430 | $5,158 | 38.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $4,500 | $3,252 | 72.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 97 | 418 | $7,524 | $3,227 | 42.9% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2020 | 15 | 126 | $7,560 | $3,049 | 40.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 23 | $4,560 | $2,974 | 65.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 100 | 435 | $4,350 | $1,297 | 29.8% |
| 99497 | Advance care planning by the physician or other qualified health care professional | Office | 2020 | 15 | 15 | $2,250 | $978.69 | 43.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 11 | 51 | $1,785 | $632.94 | 35.5% |
About Dr. Robert Moss, M.D
Dr. Robert Moss, M.D is a Hematology & Oncology healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861503609.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Moss, M.D has received a total of $103,336 in payments from pharmaceutical and medical device companies, with $21.23 received in 2024. These payments were reported across 671 transactions from 59 companies. The most common payment nature is "" ($79,632).
As a Medicare-enrolled provider, Moss has provided services to 438 Medicare beneficiaries, totaling 1,812 services with total Medicare billing of $82,408. Data is available for 1 year (2020–2020), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fountain Valley, CA
- Active Since 08/31/2006
- Last Updated 01/20/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1861503609
Products in Payments
- EMPLICITI (Biological) $70,169
- RUBRACA (Drug) $3,428
- SUSTOL (Drug) $2,780
- Afatinib (Drug) $2,470
- SOLIRIS (Drug) $976.06
- OPDIVO (Biological) $929.10
- KEYTRUDA (Biological) $921.85
- DARZALEX (Biological) $785.22
- IMFINZI (Drug) $533.22
- LYNPARZA (Drug) $531.35
- Nerlynx (Drug) $483.89
- KISQALI (Drug) $447.00
- Perjeta (Biological) $435.25
- Cabometyx (Drug) $421.95
- JAKAFI (Drug) $384.31
- XTANDI (Drug) $358.70
- Revlimid (Drug) $355.43
- TAGRISSO (Drug) $297.00
- RYDAPT (Drug) $235.20
- Kyprolis (Biological) $235.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fountain Valley
Dr. Lalita Pandit, M.d, M.D
Hematology & Oncology — Payments: $72,643
Hematology & Oncology $72,643
Amol Rao, M.d, M.D
Hematology & Oncology — Payments: $57,618
Hematology & Oncology $57,618
Peyman Salimi-Tari, M.d, M.D
Hematology & Oncology — Payments: $51,086
Hematology & Oncology $51,086
Steven Yu, Md, MD
Hematology & Oncology — Payments: $31,830
Hematology & Oncology $31,830
Kevin Do
Hematology & Oncology — Payments: $22,848
Hematology & Oncology $22,848
Dr. Collin Vu, M.d, M.D
Hematology & Oncology — Payments: $18,185
Hematology & Oncology $18,185